DelveInsight’s, “Extensive Stage Small Cell Lung Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Extensive Stage Small Cell Lung Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Extensive Stage Small Cell Lung Cancer Clinical studies, NDA approvals (if any), and product development activities comprising the technology, Extensive Stage Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Extensive Stage Small Cell Lung Cancer Pipeline Report
Recent Developmental Activities in the Extensive Stage Small Cell Lung Cancer Pipeline Report
Request a sample and discover the recent breakthroughs happening Extensive Stage Small Cell Lung Cancer Treatment Landscape Analysis Report @ Extensive Stage Small Cell Lung Cancer Clinical Trials Analysis
Extensive Stage Small Cell Lung Cancer Overview
Extensive Stage Small Cell Lung Cancer is in the stage where it has spread to other parts of the body, such as the other lung or the brain. Without treatment, the average life expectancy for a person with an extensive-stage small cell lung cancer diagnosis is two to four months. The liver, adrenal glands, and bone are also common sites of metastasis. Though extensive-stage small cell lung cancer cannot be cured and has a poor prognosis, it may respond to chemotherapy and newer treatments. Because the cancer has spread, the main treatment for extensive stage SCLC is chemotherapy. Common chemo drugs used for ESCLC are: carboplatin and cisplatin. Other therapies used to treat ESCLS include: immunotherapy and radiation therapy.
Extensive Stage Small Cell Lung Cancer Emerging Drugs
LY 2510924: Eli Lilly and Company
LY-2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration, CXCR4 inhibitor LY-2510924 binds to the chemokine receptor CXCR4, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation.
Tiragolumab: Genentech
Tiragolumab is a monoclonal antibody designed to bind with TIGIT, a protein receptor on immune cells. Tiragolumab works as an immune amplifier, by potentially enhancing the body’s immune response. By binding to TIGIT, tiragolumab blocks its interaction with a protein called poliovirus receptor (PVR, or CD155) that can suppress the body’s immune response. Blockade of TIGIT and PD-L1 may synergistically enable the re-activation of T cells and enhance NK cell anti-tumor activity. It is in phase 3 stage of development for the treatment of Extensive-Stage Small Cell Lung Cancer.
Extensive Stage Small Cell Lung Cancer Pipeline Therapeutics Analysis
There are approx. 40+ key companies which are developing the therapies for Extensive Stage Small Cell Lung Cancer (ESCLC). The companies which have their Extensive Stage Small Cell Lung Cancer (ESCLC) drug candidates in the most advanced stage, i.e. phase III include, Genentech.
Learn more about the Extensive Stage Small Cell Lung Cancer emerging pipeline therapies @ Extensive Stage Small Cell Lung Cancer Pipeline Drugs
Scope of the Extensive Stage Small Cell Lung Cancer Pipeline Report
Table of Content
Key Questions
Current Treatment Scenario and Emerging Therapies:
Got Queries? Reach out for more information on the Extensive Stage Small Cell Lung Cancer Pipeline Report @ Extensive Stage Small Cell Lung Cancer Treatment
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/